Cytokinetics Q3 net loss $129.4M ($1.35/sh); SEQUOIA-HCM topline late Dec.

CYTOKINETICS INC

2023-Q3 EPS reported -$4.07 revenue$5,858,000

Net loss for Q3 2023 was $129.4M ($1.35/diluted share) vs $142.3M ($1.52) in Q3 2022.
Cash, cash equivalents and investments totaled $554.7M at Sep 30, 2023; received $50M milestone from Royalty Pharma.
Q3 revenue dropped to $0.4M from $2.5M YoY; nine-month revenue $5.9M vs $92.6M prior.
Topline results from pivotal Phase 3 SEQUOIA-HCM (aficamten in obstructive HCM) expected late December.
Submitted formal dispute resolution to FDA regarding omecamtiv mecarbil CRL; EMA responses submitted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CYTOKINETICS INC reported third quarter ended September 30, 2023 results: net income $129.4 million, EPS $1.35 per share.

Period: third quarter ended September 30, 2023
Net income: $129.4 million
EPS: $1.35 per share
Result: reported results

Exact text from the filing

Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023. Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share.

View on SEC.gov

14 earnings releases filed in the last 30 days. Browse all earnings releases →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-058172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.